Jenburkt Pharmaceuticals profitability ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Margins
Returns					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	18.8%	20.3%	19.4%	20.5%
	16.5%	17.8%	16.9%	17.3%
	23.8%	24.5%	21.5%	20.3%
	23.8%	24.5%	21.5%	20.3%
	17.4%	68.9%	53.0%	—
	29.9%	29.0%	24.8%	24.0%
	20.6%	21.1%	18.3%	18.0%
	15.7%	18.4%	5.7%	12.5%
Additional
	18.8%	20.3%	19.4%	20.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

JENBURPH₹872.30

Jenburkt Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersBPLPHARMA KPL MAKERSL NOVARTIND PARNAXLAB SGRL SHUKRAPHAR SUNLOC

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
Returns
Return on Common Equity	20.53	19.43	20.25	18.84
Return on Assets	17.28	16.93	17.75	16.45
Margins
EBITDA Margin	20.29	21.49	24.53	23.81
Operating Margin	20.29	21.49	24.53	23.81
Incremental Operating Margin	—	53.04	68.92	17.35
Pretax Margin	24.03	24.78	28.96	29.91
Net Income Margin	17.99	18.30	21.14	20.59
FCF Margin	12.47	5.72	18.40	15.72
Additional
Sustainable Growth Rate	20.53	19.43	20.25	18.84

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.